|
|
|
|
|
|
|
VIT B6 REQUIREMENT IS INCREASED BY THE DRUG
|
ISONIAZID REDUCES ITS PLASMA CLEARANCE BY 50%
|
ISONIAZID REDUCES ITS PLASMA CLEARANCE BY 50%
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
ETHIONAMIDE MAY POTENTIATE THE ADVERSE EFFECTS OF OTHER ANTITUBERCULOSIS DRUGS ADMINISTERED CONCOMITANTLY
|
ETHIONAMIDE HAS BEEN FOUND TO TEMPORARILY RAISE SERUM CONCENTRATIONS OF ISONIAZID
|
ISONIAZID, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
ISONIAZID, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PYRAZINAMIDE HAS SYNERGISTIC ACTION WITH ISONIAZID BUT REDUCES ITS SERUM CONCENTRATION ALSO
|
INCREASED POTENTIAL FOR HEPATOTOXICITY
|
FOLIC ACID DEFICIENCY MAY PRECIPITATE WITH CONCURRENT USE
|
ISONIAZID CAUSES HYPERPYREXIA, TREMOR & DEATH ON CONCURRENT USE
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
CYCLOSPORINE SERUM LEVELS ARE REDUCED BY THE DRUG
|
ACARBOSE ACTION IS POTENTIATED BY THE DRUG
|
KETOCONAZOLE REDUCES ITS PLASMA CONCENTRATION
|
KETOCONAZOLE REDUCES ITS PLASMA CONCENTRATION
|
KETOCONAZOLE REDUCES ITS PLASMA CONCENTRATION
|
KETOCONAZOLE REDUCES ITS PLASMA CONCENTRATION
|
CO-ADMINISTRATION CAN INCREASE PLASMA LEVELS OF CICLESONIDE LEADING TO INCREASED CHANCES OF CUSHING SYNDROME
|
MAY POTENTIALLY INCREASE THE RISK FOR ACETAMINOPHEN INDUCED HEPATOTOXICITY
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
PREDNISOLONE DECREASES ITS SERUM LEVEL
|
PREDNISOLONE DECREASES ITS SERUM LEVEL
|
PREDNISOLONE DECREASES ITS SERUM LEVEL
|
PREDNISOLONE DECREASES ITS SERUM LEVEL
|
PREDNISOLONE DECREASES ITS SERUM LEVEL
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|